Daily Briefing

3 minute read

Around the nation: ACS updates prostate cancer screening guidelines


The American Cancer Society has released new screening guidelines for prostate cancer for the first time in 10 years, in today's bite-sized hospital and health industry news from the District of Columbia, Georgia, and North Carolina.  

  • District of Columbia: According to the Department of Justice, three foreign nationals have been arrested and charged in connection with an alleged fraud scheme that stole over $129 million from companies worldwide between 2024 and 2026, including two hospital systems. Of the victims, one was a Missouri-based hospital system that allegedly lost $4.83 million, and another was a California-based hospital system that lost $2.97 million. According to the indictment, the defendants and their co-conspirators used AI to mimic the voices and images of CEOs and attorneys who worked at major international law firms. The perpetrators would contact employees while posing as their organization's CEO and claim to need assistance with a confidential financial transaction. Employees were also directed to contact attorneys purportedly working on the transaction, whom the perpetrators also impersonated. Each of the defendants faces seven charges, including conspiracy to commit wire fraud, aggravated identity theft, and money laundering. (Condon, Becker's Hospital Review, 11/9)
  • Georgia: The American Cancer Society (ACS) has released new screening guidelines for prostate cancer for the first time in over 10 years. Previously, ACS did not recommend routine testing for prostate cancer for men of any age and said that patients should discuss the potential risks and benefits of screening with their doctors. In the new guidelines, ACS recommends that most men between the ages of 50 and 69 get a blood test to check for prostate cancer every two years. For people with a higher risk of the disease, including Black men and those with a family history of prostate cancer, ACS recommends getting a blood test annually between the ages of 45 and 69. Men who have elevated prostate-specific antigen (PSA) levels in their blood should have follow-up testing with an MRI to determine if a prostate biopsy is needed. According to the Washington Post, the new ACS guidelines currently differ from most guidance on prostate cancer screening, with many being hesitant to recommend PSA testing due to concerns of overtreatment. However, new data has supported the effectiveness of PSA testing. For example, a European study of roughly 160,000 men found that PSA testing helped reduce prostate cancer mortality by 13%. "In 2010 … there was a concern at that point that it was unclear if the potential harms of screening outweighed the benefits," said William Dahut, chief scientific officer of ACS. "Now, we're actually recommending screening." (Wu, Washington Post, 11/12)
  • North Carolina: Novant Health has named John Gizdic, the system's current EVP and COO, to serve as president and interim CEO following the retirement of current president and CEO Carl Armato at the end of the year. Armato will step down on Jan. 1 after almost 30 years at Novant, half of which was spent as the system's president and CEO. During Armato's tenure, he grew Novant's annual operating revenue from $3.5 billion to almost $12 billion and its net assets from $2.2 billion to $8.2 billion. Gizdic has served as Novant's COO since May 2024, and before that he was the organization's chief administrative officer for three years. Previously, he spent 15 years at New Hanover Regional Medical Center, which Novant acquired in 2021. According to Christine Katziff, chair of Novant's board, the board unanimously decided that Gizdic was the right choice to lead the organization during its CEO transition, citing his "operational excellence, strategic vision, hands-on experience, and deep industry expertise." (LaPointe, Healthcare Dive, 11/11)

SPONSORED BY

INTENDED AUDIENCE

AFTER YOU READ THIS

AUTHORS

TOPICS

INDUSTRY SECTORS

RELATED RESOURCES

Don't miss out on the latest Advisory Board insights

Create your free account to access 1 resource, including the latest research and webinars.

Want access without creating an account?

   

You have 1 free members-only resource remaining this month.

1 free members-only resources remaining

1 free members-only resources remaining

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

This content is available through your Curated Research partnership with Advisory Board. Click on ‘view this resource’ to read the full piece

Email ask@advisory.com to learn more

Click on ‘Become a Member’ to learn about the benefits of a Full-Access partnership with Advisory Board

Never miss out on the latest innovative health care content tailored to you. 

Benefits Include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

This is for members only. Learn more.

Click on ‘Become a Member’ to learn about the benefits of a Full-Access partnership with Advisory Board

Never miss out on the latest innovative health care content tailored to you. 

Benefits Include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox
AB
Thank you! Your updates have been made successfully.
Oh no! There was a problem with your request.
Error in form submission. Please try again.